Market Closed - Nasdaq Stockholm 11:29:40 2024-04-26 am EDT 5-day change 1st Jan Change
0.23 SEK -1.08% Intraday chart for Acarix AB -6.12% +21.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study CI
Acarix Announces the Results from 2024 American College of Cardiology Poster Presentation to Assess the Cost-Utility of the Cadscor System CI
Transcript : Acarix AB, Q4 2023 Earnings Call, Feb 15, 2024
Acarix Appoints New Members to the Advisory Board CI
Acarix AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Acarix AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Acarix Seeks SEK33.7 Million from Share Issuance MT
Acarix Names New CEO MT
Acarix AB Announces CEO Changes CI
Acarix AB Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network CI
Transcript : Acarix AB, Q3 2023 Earnings Call, Nov 09, 2023
Acarix AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Acarix AB - Special Call
Acarix CEO to Take Medical Leave; Acting CEO Appointed MT
Acarix AB Announces CEO Changes CI
Acarix AB Appoints Christian Lindholm as Executive Vice President CI
Acarix AB Expands Use of CADScor System into Osteopathic Medicine CI
Acarix Targets SEK54 Million in Rights Issue; Shares Down MT
Acarix, Maeva Health to Launch Coronary Artery Disease Medical Device in Mauritius, East Africa MT
Acarix AB Receives Initial Order from the Emerging East African Market CI
Transcript : Acarix AB, Q2 2023 Earnings Call, Aug 31, 2023
Acarix AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
First Veterans Affairs Healthcare System Standardizes Use of Acarix CADScor System CI
Acarix AB Appoints Dr. Deepak R. Talreja Md as New Medical Advisor CI
Transcript : Acarix AB - Special Call
Chart Acarix AB
More charts
Acarix AB is a Sweden-based provider of diagnostic solutions for coronary artery disease (CAD). The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock Market
  2. Equities
  3. ACARIX Stock
  4. News Acarix AB
  5. Acarix CEO to Take Medical Leave; Acting CEO Appointed